Article
The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine.
Clinical pharmacology and therapeutics - 1 Jan 1993
Ujhelyi M R, O'Rangers E A, Fan C, Kluger J, Pharand C, Chow M S
Abstract excerpt
Although propafenone is a known substrate and inhibitor of the cytochrome P450 4-hydroxylation pathway of debrisoquin (CYP2D6 isozyme), its effects on other hepatic mixed- function oxidative isozymes have not been extensively evaluated. We studied the influence of propafenone on the disposition of continuously infused lidocaine in 12 healthy male volunteers. Placebo or propafenone (225 mg every 8 hours) was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.